Candel Therapeutics (CADL) Operating Expenses (2020 - 2025)

Candel Therapeutics has disclosed Operating Expenses across 6 years of filings, most recently posting $15.8 million for Q4 2025.

• Operating Expenses for Q4 2025 came in at $15.8 million, up 93.49% year-over-year; the trailing twelve-month figure through Dec 2025 was $48.3 million (up 44.63% YoY), and the FY2025 annual result was $48.3 million, up 44.63% from the prior year.
• Operating Expenses came in at $15.8 million for Q4 2025 at Candel Therapeutics, up from $13.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $15.8 million in Q4 2025 to a low of $4.7 million in Q1 2021.
• The 5-year median for Operating Expenses is $8.8 million (2022), against an average of $9.0 million.
• Across the five-year window, Operating Expenses surged 189.93% in 2021 and retreated 21.1% in 2024, its largest moves.
• Candel Therapeutics' Operating Expenses stood at $7.8 million in 2021, then increased by 4.65% to $8.1 million in 2022, then increased by 26.88% to $10.3 million in 2023, then retreated by 21.1% to $8.1 million in 2024, then soared by 93.49% to $15.8 million in 2025.
• The last three Operating Expenses figures came in at $15.8 million (Q4 2025), $13.2 million (Q3 2025), and $11.2 million (Q2 2025), per Business Quant data.